Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis

Inflammation Research

Volumn 57, Issue 12, 2008, Pages 586-592

  Bressan, E ^a   Tonussi, C R ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Etoricoxib; Gastric damage; Indomethacin; Leukocyte migration; LPS induced reactive arthritis; Piroxicam

Indexed keywords

ETORICOXIB; INDOMETACIN; PIROXICAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG POTENCY; EDEMA; KNEE; LEUKOCYTE COUNT; LEUKOCYTE MIGRATION; MALE; MONONUCLEAR CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; RAT; REACTIVE ARTHRITIS; STOMACH HEMORRHAGE; STOMACH INJURY; SYNOVIAL FLUID; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; INDOMETHACIN; KNEE JOINT; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; PAIN MEASUREMENT; PIROXICAM; PYRIDINES; RATS; RATS, WISTAR; SULFONES; SYNOVIAL FLUID;

EID: 58149127500     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-8029-2     Document Type: Article

References (50)

1. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clinical Microbiology Reviews 2004; 17(2): 348-69.
2. Palazzi C, Olivieri I, D'Amico E, Pennese E, Petricca A. Management of reactive arthritis. Expert Opinion on Pharmacotherapy 2004; 5(1): 61-70.
3. Reveille JD, Arnett, FC. Spondyloarthritis: update on pathogenesis and management. The American Journal of Medical Electronics 2006; 118(6): 592-603.
4. Hamdulay SS, Glynne SJ, Keat A. When is arthritis reactive? The Nigerian Postgraduate Medical Journal 2006; 82(969): 446-53.
5. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. The New England Journal of Medicine 1999; 340: 1888-1899.
7. Fiorucci S, Santucci L, Distrutti E. NSAIDs, COXIBs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Digestive and Liver Disease 2007; 39: 1043-51.
8. Niederberger E, Manderscheid C, Geisslinger G. Different COXindependent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochemical Biophysical Research Communications 2006; 342(3): 940-8.
9. Hermann E, Fleischer B, Meyer zum Buschenfelde KH. Bacteria-specific cytotoxic CD8+ T cells: a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies. Annals of Internal Medicine 1994; 26(5): 365-9.
10. Allen RL, Gillespie GM, Hall F, Edmonds S, Hall MA, Words-worth BP, et al. Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis. The Journal of Rheumatology, 1997; 24(9): 1750-7.
11. Yu DT. Pathogenesis of reactive arthritis. Advances in Internal Medicine 1999; 38(2): 97-101.
12. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Annals of the Rheumatic Diseases 2000; 59(2): 135-40.
13. Marker-Hermann E, Schwab P. T-cell studies in the spondyloarthropathies. Current Rheumatology Reports 2000; 2(4): 297-305.
14. Hill Gaston JS, Lillicrap MS. Arthritis associated with enteric infection. Best Practice & Research Clinical Rheumatology 2003; 17(2): 219-39.
15. International Association For Study of Pain (IASP). Ethical guidelines for investigation of experimental pain in conscious animals. Pain 1983, 16: 109-10.
16. Bressan E, Cunha FQ, Tonussi CR. Contribution of TNFalpha, IL-1beta and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis. Cytokine 2006; 36(1-2): 83-9.
17. Tonussi CR and Ferreira SH. Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain 1992; 48(3): 421-7.
18. Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990; 335(8691): 685-8.
19. Granfors K, Jalkanen S, Von Essen R, Iahesmaa-Rantala R, Isomaki O, Pekkola-heino K, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. The New England Journal of Medicine 1989; 320(4): 216-21.
20. Sieper J, Braun J, Kingsley GH. Report on the Fourth International Workshop on Reactive Arthritis. Arthritis Rheumatism 2000; 43(4): 720-34.
21. Huppertz HI, Heesemann J. Experimental Yersinia infection of human synovial cells: persistence of live bacteria and generation of bacterial antigen deposits including "ghosts," nucleic acid-free bacterial rods. Infection and Immunology 1996; 64(4): 1484-7.
22. Fearon U, Veale DJ. Pathways of cell activation in spondyloarthropathies. Current Rheumatology Reports 2001; 3(5): 435-42.
23. Masson G, Thomas P, Bontoux D, Alcalay M. Influence of trauma on initiation of Reiter's syndrome and ankylosing spondylitis. Annals of the Rheumatic Diseases 1985; 44(12): 860-1.
24. Alcalay M, Debiais F, Azais I, Bontoux D. Post-traumatic reactive arthritis. Etiologic, clinical and diagnostic aspects. Apropos of 6 cases. Revue Rhumatisme et des Maladies Ostéo-articulaires 1989; 56: 725-9.
25. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. The Journal of Pharmacology and Experimental Therapeutics 2001; 296(2): 558-66.
26. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America 1994; 90(24): 11693-7.
27. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. Journal of Rheumatology 1999; 26(6): 1366-73.
28. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. Journal of Pharmacy and Pharmacology 2001; 53(12): 1679-85.
29. Fiorucci S, Santucci L, Gerli R, Brunori PM, Federici B, Ugolini B, et al. NSAIDs upregulate beta 2-integrin expression on human neutrophils through a calcium-dependent pathway. Alimentary Pharmacology & Therapeutics 1997; 11(3): 619-30.
30. Bender JG, Van Epps DE, Searles R, Williams RC Jr. Altered function of synovial fluid granulocytes in patients with acute inflammatory arthritis: evidence for activation of neutrophils and its mediation by a factor present in synovial fluid. Inflammation 1986; 10(4): 443-53.
31. Edwards SW, Hughes V, Barlow J, Bucknall R. Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis. The Biochemical Journal 1988; 250(1): 81-5.
32. Higgs GA, Eakins KE, Mugridge KG, Moncada S, Vane JR. The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. European Journal of Pharmacology 1980; 66(1): 81-6.
33. Gonçalves de Moraes VL, Boris Vargaftig B, Lefort J, Meager A, Chignard M. Effect of cyclooxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung. British Journal of Pharmacolology 1996; 117(8): 1792-6.
34. Pettipher ER, Henderson B, Edwards JC, Higgs GA. Effect of indomethacin on swelling, lymphocyte influx, and cartilage proteoglycan depletion in experimental arthritis. Annals of the Rheumatic Diseases 1989; 48(8): 623-7.
35. Egan CG, Lockhart JC, McLean JS, Ferrell WR. Expression of constitutive but not inducible cyclooxygenase maintains articular perfusion in the rat knee. Experimental Physiology 2001; 86(2): 191-7.
36. Egan CG, Lockhart JC, Ferrell WR. Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation. Journal of Physiology 2004; 557(Pt 2): 635-43.
37. Meacock SC, Kitchen EA. Some effects of non-steroidal anti-inflammatory drugs on leucocyte migration. Agents Actions 1976; 6(1-3): 320-5.
38. Vinegar R, Truax JF, Selph JL, Lea A, Johnston PR. Quantitative in vivo studies of the acute actions of anti-inflammatory drugs in the rat. European Journal of Reumatology and Inflammation 1978; 3(1): 204-11.
39. Lo TN, Almeida AP, Beaven MA. Dextran and carrageenan evoke different inflammatory responses in rat with respect to composition of infiltrates and effect of indomethacin. The Journal of Pharmacology and Experimental Therapeutics 1982; 221(1): 261-7.
40. Pinheiro RM, Calixto JB. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflammation Research 2002; 51(12): 603-10.
41. Yuhki K, Ueno A, Naraba H, Kojima F, Ushikubi F, Narumiya S, Oh-ishi S. Prostaglandin receptors EP2, EP3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy. The Journal of Pharmacology and Experimental Therapeutics 2004; 311(3): 1218-24.
42. Menezes GB, dos Reis WG, Santos JM, Duarte ID, de Francischi JN. Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase-2 inhibitors accounts for reduced rat leukocyte migration. Inflammation 2005; 29(4-6): 163-9.
43. Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase-1 and cyclooxygenase-2) in acute inflammation. European Journal of Pharmacology 1998; 355(2-3): 211-7.
44. Schiantarelli P, Cadel S. Piroxicam pharmacologic activity and gastrointestinal damage by oral and rectal route. Comparison with oral indomethacin and phenylbutazone. Arzneimittelforschung 1981; 31(1): 87-92.
45. Holzhausen M, Spolidorio DM, Muscara MN, Hebling J, Spolidorio LC. Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats. Journal of Periodontal Research 2005; 40(3): 208-11.
46. Gebhard HH, Zysk SP, Schmitt-Sody M, Jansson V, Messmer K, Veihelmann A. The effects of Celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis. Clinical and Experimental Rheumatology 2005; 23(1): 63-70.
47. De Souza IA, Franco-Penteado CF, Camargo EA, Lima CS, Teixeira SA, Muscara MN, et al. Inflammatory mechanisms underlying the rat pulmonary neutrophil influx induced by airway exposure to staphylococcal enterotoxin type A. British Journal of Pharmacology 2005; 146(6): 781-91.
48. Wallace J. COX-2: A Pivotal Enzyme in Mucosal Protection and Resolution of Inflammation. The Scientific World Journal 2006; 6: 577-88.
49. Dubois RW, Melmed GY, Henning JM, Bernal M. Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature. Journal of Clinical Rheumatology 2004; 10(4): 178-89.
50. Kotani T, Kobata A, Nakamura E, Amagase K, Takeuchi K. Roles of cyclooxygenase-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach. The Journal of Pharmacology and Experimental Therapeutics 2006; 316(2): 547-55.